<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43499">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01845025</url>
  </required_header>
  <id_info>
    <org_study_id>CFOR258D2416</org_study_id>
    <nct_id>NCT01845025</nct_id>
  </id_info>
  <brief_title>Study of Safety of Foradil in Patients With Persistent Asthma</brief_title>
  <official_title>A 26 Week, Randomized, Active-controlled Safety Study of Double-blind Formoterol Fumarate in Free Combination With an Inhaled Corticosteroid Versus an Inhaled Corticosteroid in Adolescent and Adult Patients With Persistent Asthma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether the risk of serious asthma-related events
      (asthma-related hospitalizations, asthma related intubations, and asthma related deaths) in
      adolescents and adults (12 years of age and older) taking inhaled formoterol
      fumarate/fluticasone propionate combination is the same as those taking inhaled fluticasone
      propionate alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 26 week, double blind, randomized, active-controlled safety study of Foradil in
      free combination with inhaled corticosteroid versus an inhaled corticosteroid alone in
      adults and adolescent patients with persistent asthma. The primary objective of the study is
      to demonstrate that the addition of formoterol fumarate to fluticasone propionate is
      non-inferior to fluticasone propionate alone in terms of the risk of composite serious
      asthma related events (asthma-related hospitalization, asthma-related intubation, and
      asthma-related death). The individual components of the composite primary endpoint (i.e.,
      asthma-related hospitalization, asthma-related intubation and asthma-related death) will be
      assessed as a secondary safety endpoints.

      The efficacy assessment is the secondary objective.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Combined serious asthma related events</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Combined number of asthma-related hospitalization, asthma-related intubation, and asthma-related death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Asthma-related hospitalization</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of asthma-related hospitalizations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma-related intubation</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of asthma-related intubation events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma-related deaths</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of asthma-related deaths</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue medication use</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Frequency of rescue medication use during study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom and rescue-free days</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of symptom and rescue-free days per patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nighttime awakenings</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of nighttime awakenings per patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma control Questionnaire (ACQ - 6) score</measure>
    <time_frame>baseline and 26 weks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in Asthma control Questionnaire (ACQ - 6) score from baseline</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">11700</enrollment>
  <condition>Persistent Asthma</condition>
  <arm_group>
    <arm_group_label>Formoterol + fluticasone propionate 100 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formoterol 12 mcg + fluticasone propionate 100 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formoterol + fluticasone propionate 250 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formoterol 12 mcg + fluticasone propionate 250 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formoterol + fluticasone propionate 500 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formoterol 12 mcg + fluticasone propionate 500 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluticasone propionate 100 mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo + fluticasone propionate 100 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluticasone propionate 250 mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo + fluticasone propionate 250 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluticasone propionate 500 mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo + fluticasone propionate 500 mcg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol</intervention_name>
    <description>Formoterol 12 mcg one inhalation twice daily, via dry powder inhaler</description>
    <arm_group_label>Formoterol + fluticasone propionate 100 mcg</arm_group_label>
    <arm_group_label>Formoterol + fluticasone propionate 250 mcg</arm_group_label>
    <arm_group_label>Formoterol + fluticasone propionate 500 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone propionate 100 mcg</intervention_name>
    <description>Fluticasone propionate 100 mcg one inhalation twice daily via dry powder inhaler</description>
    <arm_group_label>Formoterol + fluticasone propionate 100 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone propionate 250 mcg</intervention_name>
    <description>Fluticasone propionate 250 mcg one inhalation twice daily via dry powder inhaler</description>
    <arm_group_label>Formoterol + fluticasone propionate 250 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone propionate 500 mcg</intervention_name>
    <description>Fluticasone propionate 500 mcg, one inhalation twice daily via dry powder inhaler</description>
    <arm_group_label>Formoterol + fluticasone propionate 500 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to formoterol one inhalation twice daily via dry powder inhaler</description>
    <arm_group_label>Fluticasone propionate 100 mcg</arm_group_label>
    <arm_group_label>Fluticasone propionate 250 mcg</arm_group_label>
    <arm_group_label>Fluticasone propionate 500 mcg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent, and assent if applicable, must be obtained before any
             assessment is performed.

          2. Male or female patients 12 years of age and older

          3. Confirmed diagnosis of persistent asthma, as defined by national and international
             asthma guidelines (e.g., GINA; NIH; etc.) for at least 1 year prior to study
             enrollment.

          4. PEFâ‰¥50% of predicted normal value.

          5. Current and appropriate use of one of the treatments listed in the protocol for
             asthma.

          6. Recent asthma exacerbation between 30 days and 12 months prior to randomization that
             either:

               -  required treatment with systemic corticosteroids (tablets, suspension, or
                  injection) or

               -  required hospitalization (defined as an inpatient stay or &gt;24-hour stay in an
                  observation area in an emergency room or other equivalent facility)

        Exclusion Criteria:

          1. History of life-threatening asthma episode that required intubation and/or was
             associated with hypercapnia requiring non-invasive ventilatory support.

          2. Current evidence of pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease,
             allergic bronchopulmonary aspergillosis, cystic fibrosis, bronchopulmonary dysplasia,
             or other respiratory abnormalities other than asthma.

          3. Current evidence of, or past physician assessment of, chronic bronchitis, emphysema,
             or chronic obstructive pulmonary disease.

          4. History of smoking â‰¥ 10 pack years.

          5. Exercise induced asthma (as the only asthma-related diagnosis) not requiring daily
             asthma control medicine.

          6. Suspected or documented bacterial or viral infection of the upper or lower
             respiratory tract, sinus or middle ear that is not resolved at randomization.

          7. Worsening/Unstable asthma within 7 days prior to randomization.

          8. Any asthma exacerbation requiring systemic corticosteroids within 30 days of
             randomization or more than 4 separate exacerbations in the 12 months preceding
             randomization.

          9. Two or more hospitalizations for greater than 24 hours duration for treatment of
             asthma in the 12 months preceding randomization.

         10. History of hypersensitivity to any beta2-agonist, sympathomimetic drug, inhaled
             corticosteroids, or systemic corticosteroid therapy or any component of the possible
             study treatments in this trial, including severe milk protein hypersensitivity.

         11. Use of anti-IgE (e.g., omalizumab) or any other monoclonal antibody, in the 6 months
             prior to randomization.

         12. Use of (Beta) Î²-blockers within 1 day prior to first dose of study medication.

         13. Use of ICS, LABA, ICS+LABA, LTRAs, leukotriene modifiers, anticholinergics, or
             theophylline must be discontinued prior to the first dose of investigational
             treatment.

         14. Use of a potent CYP3A4 inhibitor within 4 weeks of randomization (e.g., ritonavir,
             atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir,
             saquinavir, ketoconazole, telithromycin).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chrsitopher Compton</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Avondale</city>
        <state>Arizona</state>
        <zip>853253</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cave Creek</city>
        <state>Arizona</state>
        <zip>85331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85051</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85254</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordova</city>
        <state>Tennessee</state>
        <zip>38018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38116</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brookfield</city>
        <state>Wisconsin</state>
        <zip>53005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mequon</city>
        <state>Wisconsin</state>
        <zip>53092</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>S Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53172</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Waukesha</city>
        <state>Wisconsin</state>
        <zip>53189</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 26, 2014</lastchanged_date>
  <firstreceived_date>April 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma, formoterol fumarate, Foradil, inhaled corticosteroid, fluticasone propionate, safety</keyword>
  <keyword>Asthma</keyword>
  <keyword>formoterol fumarate</keyword>
  <keyword>Foradil</keyword>
  <keyword>inhaled corticosteroid</keyword>
  <keyword>fluticasone propionate</keyword>
  <keyword>safety</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Formoterol</mesh_term>
    <mesh_term>Fluticasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
